Text size
Bottles of the modern Covid-19 vaccine.
Guillaume Souvant / AFP via Getty Images
Modern plans to announce the development of a vaccine candidate that will protect against Covid-19 and the flu, known as mRNA-1073. The company will also announce a pediatric vaccine called mRNA-1365, which combines its experimental respiratory syncytial virus vaccine with its experimental human metapneumovirus vaccine.
The news came less than an hour before the company began an investor event aimed at discussing the company’s clinical development. Moderna’s top executives (MRNA), including CEO Stéphane Bancel, the newly appointed chief physician, Dr. Paul Burton, and the company’s president, Dr. Stephen Hoge, should appear.
Modern
shares rose 5.9% the following Thursday at the start of its virtual R&D day, scheduled for 8 a.m. in the East. Shares fell 3.1% on Wednesday, but are up 304.8% this year.
In a press release, Moderna said it planned to announce several pipeline updates at the research and development day presentation.
“Today we announce the first step of our new respiratory vaccine program with the development of a single-dose vaccine that combines COVID-19 booster and flu booster,” Bancel said in a statement. “We are making progress in enrolling patients in our rare disease programs and are fully enrolled in our personalized cancer vaccine trial. We believe this is just the beginning of a new era of information-based drugs.”
The company also said it would discuss new data from a phase 1 study of its respiratory syncytial virus vaccine. The company said provisional data from the study showed that a single vaccine with the vaccine, known as mRNA-1345, increased neutralizing antibody titers against RSV-A virus 14 times and against RSV-A virus. B in 10 times. The company tested three different dose levels, but said there was no significant difference in antibody response between dose levels.
The company said it plans to begin a phase 2/3 study of the RSV vaccine later this year.
Moderna was a very different company at the time of its last virtual R&D day in September 2020. It was still a clinical phase company at the time, Moderna had no authorized or approved products. That changed months later, when the U.S. Food and Drug Administration authorized Moderna’s Covid-19 vaccine, which is expected to generate $ 20.1 billion in revenue this year alone.
At the time, Moderna established a development pipeline that included its Covid-19 vaccine, custom cancer vaccines, and other products, including a range of prophylactic vaccine programs.
He also announced for the first time that day that he planned to develop a flu vaccine.
Write to [email protected]